Home › NDC Lookup › RxCUI directory › RxCUI 1986813

Acalabrutinib 100 MG Oral Capsule — RxCUI 1986813

RxNorm drug concept · Semantic clinical drug
RxCUI 1986813 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 0 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1986813
Official nameAcalabrutinib 100 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped0
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Acalabrutinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Calquence targets a specific protein inside cancer cells called BTK that acts like a growth switch. By permanently blocking that switch, it cuts off the signal that tells your canc...
  • What exactly is Calquence treating in my body?
  • Good news — you can take Calquence with or without food, so work it into your routine however is easiest. The one thing to watch for is acid-reducing medicines: if you take the cap...
  • The most common things people notice are headaches, diarrhea, fatigue, muscle aches, and upper respiratory infections like colds. Bruising more easily than usual is also pretty com...
📖 Read our full Acalabrutinib guide →

🕸️ Concept Web — How Acalabrutinib 100 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Acalabrutinib 100 MG Oral Capsule RxCUI 1986813

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Acalabrutinib 1986808
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Calquence 1986814
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Acalabrutinib Oral Capsule 1986812
    • Acalabrutinib Oral Product 1986810
    • Acalabrutinib Pill 1986811
    • Acalabrutinib Oral Capsule [Calquence] 1986816
    • Calquence Oral Product 1986817
    • Calquence Pill 1986818
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Acalabrutinib 100 MG SCDC · 1986809
  • Acalabrutinib Oral Capsule SCDF · 1986812
  • Acalabrutinib Oral Product SCDG · 1986810
  • Acalabrutinib Pill SCDG · 1986811

Brand-Name Concepts

  • Acalabrutinib 100 MG Oral Capsule [Calquence] SBD · 1986819
  • Acalabrutinib 100 MG [Calquence] SBDC · 1986815
  • Acalabrutinib Oral Capsule [Calquence] SBDF · 1986816
  • Calquence Oral Product SBDG · 1986817
  • Calquence Pill SBDG · 1986818
  • Calquence BN · 1986814

📦 FDA Products & Package NDCs

1 product · 0 package NDCs
No package NDCs are mapped to this concept in the current snapshot. Missing rows here mean the openFDA export did not annotate a listing with this RxCUI — never that no product exists.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.